Lupilan Special Precautions

Elderly Patients with Dementia-Related Psychosis: Increased risk of death and increased of cerebrovascular adverse events (e.g., stroke, transient ischemic attack).
Suicide: The possibility of a suicide attempt is inherent in schizophrenia and in bipolar disorder, and close supervision of high risk patients should accompany drug therapy, when using in combination with fluoxetine.
Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring.
Hyperglycemia: In some cases extreme and associated with ketoacidosis or hyperosmolar coma or death has been reported in patients taking olanzapine. Patients taking olanzapine should be monitored for symptoms of hyperglycemia and undergo fasting blood glucose testing at the beginning of and periodically during treatment.
Hyperlipidemia: Undesirable alterations in lipids have been observed. Appropriate clinical monitoring is recommended including fasting blood lipid testing at the beginning of the periodically during treatment.
Weight gain: Potential consequences of weight gain should be considered. Patients should receive regular monitoring of weight.
Tardive Dyskinesia: Discontinue if clinically appropriate.
Orthostatic Hypotension: Orthostatic hypotension associated with dizziness, tachycardia, bradycardia and in some patients syncope may occur especially during initial dose titration.
Seizures: Use cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold.
Potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Use caution when operating machinery.
Hyperprolactinemia: May elevate prolactin levels.
Laboratory Tests: Monitor fasting blood glucose and lipid profiles at the beginning of and periodically during treatment.